Hemophilia A is a genetic disorder characterized by the deficiency of clotting factor VIII, leading to prolonged bleeding episodes. Advances in treatment have significantly improved the management ...

For centuries, hemophilia was a dangerous genetic disorder with no treatment. Children with hemophilia often didn't make it to adulthood, since a bump or fall could cause massive internal bleeding.

Growing advancements in haemophilia treatment underscore a significant shift toward targeted and long-lasting therapeutic ...

Sangamo Therapeutics’ stock has plummeted by 50% in premarket trading after Pfizer ended the companies’ partnership to co-develop a gene therapy for haemophilia A. Sangamo announced it will ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

Haemophilia a rare hereditary blood disorder that prevents proper blood clotting affects millions globally and as there is no ...

The recent announcement by the government to provide free medicines for hemophilia patients is a welcome step forward in ...

Metagenomi says it hopes to start clinical trials next year to test MGX-001, its gene-editing therapy candidate for ...

Tune into the latest EMJ Webinar, featuring five key members of the EAHAD, who discuss the EAHAD’s mission, aims, and key ...

Be Biopharma has secured $92m in a Series C financing round to advance its clinical programmes for haemophilia B and ...